Latest from University of Wisconsin Carbone Cancer Center

Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses combinations in multiple myeloma.
 
Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses treatment considerations in relapsed and refractory multiple myeloma.
 
According to a new study by UW Carbone Cancer Center researchers, a broadly applicable cancer therapy currently being developed by Cellectar Biosciences may have the potential to work in pediatric solid tumors.
PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and the indications for the use of these drugs have broadened in recent months.
Mark Burkard, MD, PhD, discusses the steps researchers are taking to address questions on genomics in breast cancer and what subtypes pose the greatest challenges.
Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the potential of future treatments for patients with HER2-positive breast cancer.
A brain tumor research group at the UW Carbone Cancer Center focuses on biological studies of patient-derived glioblastoma multiforme (GBM) cancer stem cells, combined with analysis of patient-matched serum-cultured GBM and an annotated GBM tissue microarray, to identify clinically relevant biomarkers.
Researchers at the University of Wisconsin School of Medicine and Public Health have found that removing a specific type of collagen can dramatically reduce the growth of one form of breast cancer.
Publication Bottom Border
Border Publication
x